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Conclusions: Dosimetric impact of swallowing is insignificant as 
this motion is rare, rapid and easily suppressed by patients. 
There is however a risk of systematic miss-targeting if the 
planning CT is not acquired with the larynx in resting position. 
Anatomic changes during treatment are associated with a 
laryngeal shift in a significant proportion of patients, which can 
justify the use of daily soft-tissue imaging in laryngeal IGRT. An 
8 mm ITV margin accounting for non-swallowing laryngeal motion 
in PL-IMRT would allow for a safe and significant dose reduction 
to organs at risk. 
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Purpose: The American Society for Radiation Oncology (ASTRO) 
and American Urological Association (AUA) developed post-
prostatectomy radiotherapy (RT) guidelines to aid patient 
counselling regarding adjuvant (ART) and salvage radiotherapy 
(SRT). The objective of this study was to examine awareness and 
compliance of these guidelines among Canadian radiation 
oncologists (RO) and urologists (U). 
Methods and Materials: An online 28-item survey was developed, 
pretested and distributed by Canadian Association of Radiation 
Oncology (CARO) and Canadian Urology Association (CUA) to RO 
and U that treat prostate cancer. Similarities and differences 
between RO and U were examined using Wilcoxon rank sum test 
and Chi-square test. Only p-values for significant findings 
reported. 
Results: Fifty-two out of 87 RO and 76/570 U responded to the 
survey. Ninety percent of RO and 40% U practiced in academic 
centres. Eighty-two percent of RO and 49% U had read the 
guidelines (p < 0.001). Sixty-seven percent RO and 83% U always 
informed patients about possible adverse pathological findings 
post radical prostatectomy (RP). Sixty-one percent RO and 48% U 
inform patients about uncertainty of using ART on development 
of metastatic disease and overall survival (p = 0.025). ART was 
considered for seminal vesicle invasion (77% RO, 68% U), 
extracapsular extension (72% RO, 35% U; p < 0.001), and positive 
margin (84% RO, 57% U; p = 0.004). Seventy-six percent RO and 
51% U recommended ART > 50% of the time for adverse 
pathological findings post RP (p = 0.011). Seventy-one percent 
RO and 49% U agreed that ART provided long-term biochemical 
control benefit but not overall survival benefit. Sixty-eight 
percent RO and 56% U suggest RT two to six months post-surgery. 
Percentage of respondents who always informed patients that 
detectable or rising PSA post-RP were associated with metastatic 
disease (36% RO, 46% U) or death from disease (21% RO, 19% U). 
Seventy-seven percent of RO and 93% of U always monitored 
post-RP PSA to enable early SRT (p = 0.016). Seventy-three 
percent RO and 84% U agreed that biochemical recurrence should 
be defined as detectable or rising PSA ≥ 0.2 ng/ml with second 
confirmatory level ≥ 0.2 ng/ml after RP (p = 0.199). Fifty-nine 
percent of RO and 43% U would always refer patients with 
biochemical recurrence without evidence of distant metastases 
for SRT, but 24% of RO and 3% of U would not. Ninety percent of 
RO and 70% U would inform patients that the effectiveness of RT 
for PSA recurrence is greatest when given at lower PSA values (p 
= 0.011). 
Conclusions: Considerably less U had read the guidelines 
compared to RO. There was concurrence about the level of 
awareness for some parts of the guidelines; however, other areas 
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Purpose: Peer review of radiation plans is recommended as an 
approach to improving patient safety and quality of care. 
However, peer review rounds are resource-intensive, and their 
impact on clinical care is not well-quantified. The objective of 
this study was to undertake a systematic review of the literature 
to assess the impact of peer review on clinical care. 
Methods and Materials: A systemic review of the literature was 
conducted according to PRISMA guidelines, including MEDLINE, 
EMBASE, and abstracts from relevant radiation oncology 
meetings. For inclusion, studies were required to report the 
impact of physician peer review on at least one element of 
treatment planning (e.g. target volume/organ at risk 
delineation, dose prescription, or dosimetry). Surveys in which 
radiation oncologists were asked to estimate the impact of peer 
review on treatment planning were also included to ascertain 
physician perspective on the clinical impact of peer review. 
Studies reporting central review of contours in clinical trials 
were excluded. All proportions reported represent weighted 
averages across studies. 
Results: The initial search yielded 882 potentially eligible 
studies. Full-text review was performed independently by two 
researchers, with discrepancies settled by a third. In total, 16 
studies met inclusion criteria and were included in the final 
analysis. Twelve studies, involving 12,239 patients, reported 
patient outcomes whereas, four surveys reported oncologists’ 
estimates of clinical impact. Studies were recent, with the 
majority (75%) published since 2010. Twelve studies reported on 
multiple tumour sites, while single-site studies included head 
and neck (n = 1), lung (n = 2), and breast (n = 1). In most studies, 
peer review occurred before the start of radiotherapy or within 
the first few fractions. Overall, peer review resulted in 
modifications to 10.7% of patient plans. Five studies 
differentiated between minor versus major changes and reported 
averages of 7.5% minor changes and 2.5% major changes. From 
the survey studies, oncologists estimate that modifications 
occurred in 6% of treatment plans. 
Conclusions: Based on a systematic review of the literature, 
peer review results in changes in clinical care in approximately 
one out every nine cases overall, with major changes in 
approximately one out of every 40 cases. Further research is 
required to determine the essential elements of peer review, and 
to assess the impact of peer review on clinical outcomes.  
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Purpose: Physics-based assessment tools were developed to 
utilize transmission EPID data acquired during treatment to 
reconstruct in vivo 3D dose for every fraction of patients treated 
with stereotactic body radiation therapy (SBRT). This method 
provides verification of inter-fractional dose delivery to capture 
treatment delivery errors midway through treatment, allowing 
potential corrective interventions to reduce the radiobiological 
impact on patients given the high dose per fraction delivered in 
SBRT. In this study, the two-year results of our implemented 
EPID-based dose verification system are presented. 
Methods and Materials: Based on our initial experiences, several 
enhancements were implemented to improve comparison 
between the EPID and treatment planning system 3D doses 
including, patient-specific EPID frame averaging optimization, 
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Acuros® XB commissioning for the Eclipse treatment planning 
system, and template development of specialized dose reports 
to analyze volumes defined within the patient’s structure set. In 
total, 90 lung, 18 spine, and two liver SBRT patients were treated 
from January 2014 to January 2016 using Varian 2300ix model 
linacs operated in 6MV SRS-mode. EPID reconstructed doses for 
each fraction were compared to Eclipse TPS AAA and Acuros dose 
calculations. Low dose (20% isodose) and high dose (planning 
target volume, PTV) regions were analyzed using gamma (3%/3 
mm). “Marginal” (< 90%) and “Suboptimal” (< 88%) pass rates 
were chosen based on the AAPM TG119 report. CBCTs, EPIDs, and 
linac output were investigated for all suboptimal fractions. 
Results: Improvements up to 8% in PTV γ-pass rates were 
observed when frame averaging was optimized. Furthermore, 
average γ-pass rates in the PTV improved from 89 ± 7% (AAA) to 
92 ± 5% (Acuros) for 32 lung patients, 71±15% (AAA) to 89±9% 
(Acuros) for nine spine patients, 90±3% (AAA) to 94 ± 1% (Acuros) 
for one liver patient. This was expected as Acuros is more 
accurate than AAA in calculating dose within complex 
heterogeneous media. Reasons for suboptimal fractions were 
identified as: 1) changes in patient anatomy with weight loss or 
gain, rotations, or shifts, or 2) changes in linac output, or errors 
in EPID image acquisition. Specific suboptimal cases will be 
presented to illustrate the utility of this in vivo dosimetry 
technique. 
Conclusions: In our study, γ-pass rates were higher using 
Acuros® XB for comparison and appeared to provide the most 
benefit in spine SBRT cases. With an increasing trend towards 
highly complex and high dose radiotherapy, in vivo dosimetry 
provides treatment verification of planned dose distributions. 
Furthermore, EPID in vivo dosimetry provides key information to 
permit adaptive radiotherapy approaches, potentially improving 
patient outcomes through more accurate dose delivery. Our 
results also highlight that complex treatments can be sensitive 
to changes in linac output and differences in patient orientation 
at the time of treatment with respect to the planning CT. 
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Purpose: Many individuals who use tobacco will continue to 
smoke after a cancer diagnosis and throughout treatment; 
however, the extant literature shows that many cancer patients 
are highly motivated to quit at this time. Continued smoking in 
cancer patients undergoing various treatments results in 
decreased treatment efficacy, potentially increased toxicity, 
reduced survival and increased risk of recurrence/second 
malignancy. This study aims to better understand cancer patient 
preferences for learning about smoking cessation.  
Methods and Materials: All new patients seen at Princess 
Margaret Cancer Centre between January 1, 2014 and June 30, 
2015 were asked to complete the Combined Tobacco History 
Survey as part of standard new patient assessments. Details 
collected from this survey include smoking status, second-hand 
smoke exposure, years smoked, family support and cessation 
preferences in terms of education modality. Demographic and 
tumour details were retrospectively collected from electronic 
patient records. The proportion of patients that were interested 
in each educational modality were calculated and difference by 
age and sex reported. Factors associated with smoking cessation 
educational preferences in univariate analyses were investigated 
further using multivariable regression analyses.  
Results: 9110 patients completed the survey. Among these there 
were 1691 smokers (17%). Forty-three percent were female and 
the median age was 57 years (range 18-95 years). Median years 
smoked was 30 years (range 0.5-80 years). Smokers included in 
this analysis were being treated predominantly for head and 
neck, gastrointestinal, genitourinary, gynecological and lung 
cancers. Of 1691 smokers, 1238 (73%) were willing to consider 
quitting and 953 (56%) reported a readiness to quit next month. 
Patients were most interested in getting smoking cessation 
education from pamphlets (45%) followed by telephone support 
(39%), speaking with a healthcare professional (29%), website 
(15%), support group (11%) and speaking with successful former 
smokers (9%). According to age tertiles, younger patients (≤ 45 
years) preferred receiving smoking cessation education over the 
telephone (50%; p < 0.001), while older patients (46-65 years and 
> 65 years) preferred smoking education to be provided in 
pamphlets (43% and 51% respectively; p = 0.07). In multivariable 
analyses, older patients were more likely to prefer pamphlets 
than younger patients OR 1.11 (95% CI: 1.01-1.23; p = 0.03). Sex 
and cancer site were not predictive of preference of education 
modality.  
Conclusions: Among cancer patients, older patients preferred to 
receive smoking cessation education through pamphlets and 
younger patients preferred to learn about smoking cessation over 
telephone. This highlights the importance of developing a 
tailored approach to smoking cessation for different cancer 
patient populations. These data provide an evidence base for 
future program development in cancer education. 
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Purpose: Sexual dysfunction in people with cancer is a 
significant problem. This guideline aimed to address the 
following question: “What is the effectiveness of pharmacologic 
interventions, psychosocial counselling or devices to manage 
sexual problems after cancer treatment?” 
Methods and Materials: This guideline was created with the 
support of the Program in Evidence-Based Care. We searched for 
existing systematic reviews, guidelines and relevant primary 
literature from 2003-2015. Men and women were evaluated 
separately. No restrictions were made on cancer type or study 
design. When first approaching the guideline the working group 
chose to focus on sexual disorders commonly known to arise in 
people with cancer. These included decreased desire, arousal 
disorders, pain (in women) and erectile dysfunction (in men). 
Only studies that evaluated the impact of an intervention on a 
sexual function outcome were included. 
Results: The panel made one overarching recommendation that 
there be a discussion with the patient, initiated by a member of 
the health care team, regarding sexual health and dysfunction 
resulting from the cancer or its treatment. The Expert Panel felt 
that this is vital since the additional recommendations cannot be 
used unless someone has taken the initiative to ask. There were 
numerous limitations of the existing literature. However, we 
made additional recommendations on 11 outcomes: six for 
women (sexual response, body image, intimacy/relationships, 
overall sexual function/satisfaction, vasomotor symptoms, 
genital symptoms) and five for men (sexual response, genital 
changes, intimacy/relationships, overall sexual 
function/satisfaction, vasomotor symptoms). There is a role for 
medication or devices in particular circumstances. Psychosocial 
counselling however had the largest evidentiary base for most of 
the outcomes. 
Conclusions: To our knowledge this is the first evidence based 
guideline to comprehensively evaluate interventions to improve 
sexual problems in people with cancer. The guideline will be a 
